Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotechnology company, announced the pricing of its previously announced underwritten public offering of 6.50 million shares at a price of $62.00 per share, with expected gross proceeds of approximately $403 million.
In addition, the company has granted the underwriters of the offering an option to purchase up to an additional $60.5 million in shares, approximately, for a period of 30 days.
Spyre Therapeutics is focused on developing the next generation of treatments for inflammatory bowel disease and other immune-mediated diseases. Spyre's pipeline includes investigational extended half-life antibodies, namely SPY001, SPY002, SPY003, and SPY072, as well as combination programs with those antibodies.
Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC are acting as the joint book-running managers for the offering.
SYRE has traded between $12.04 and $75 over the last year. The stock closed Tuesday's trade at $64.01, up 1.17%.
In the overnight market, SYRE is down 1.97% at $62.75.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.